Posts

Forbion raises record €2.3 billion with Eli Lilly among its backers

on
Forbion, a Netherlands-based life sciences venture firm, raised €2.3 billion (about $2.6 billion) across two funds—its largest fundraising haul to date. Eli Lilly is among the named backers, alongside Dutch pension investors MN and PGGM, Germany’s KfW Capital and the Kauffman Foundation. The raise included both existing and new investors. The funds are Forbion Growth Opportunities Fund IV, focused on later-stage biopharma, and Forbion Ventures Fund VIII, focused on therapeutics companies at various stages. Together, the funds could support around 30 companies; Forbion says it has already made initial investments. The fundraising brings the firm’s assets under management to about €7.5 billion. The reported total exceeds the roughly €2.09 billion raised for the two predecessor funds combined. Sources: Eli Lilly, PGGM and KfW Capital back Forbion's €2.3B fund for 30 biotechs — TFN Forbion, a prominent biotech investor, raises $2.6B for ... Forbion raises $2.6 billion a...

ArriVent lung cancer drug misses Phase 3 target

on

AstraZeneca opens major R&D centre in Cambridge, Massachusetts

on

Caribou halts CAR-T programs and weighs strategic options after funding shortfall

on

PulseSight reports preliminary PST-611 signals in a six-person Phase I study

on

Epkinly posts a first-line DLBCL trial win—but “best” remains unproven

on

Formycon expands AI and digital tools across biosimilar development

on

Shionogi agrees to buy IntraBio for $2 billion

on

BioSpace 40 Under 40 winners make their mark on biopharma

on

Shionogi to acquire IntraBio for $2 billion, expanding rare-disease portfolio

on

Three biotechs move toward IPOs as Lycia targets antibody degradation

on

Abbott wins FDA approval for patient-facing CardioMEMS features

on

Are physicians ready to embrace digital twins?

on